Abbott Laboratories (ABT) income statement
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3034% above fair value
$104.48−0.23 (-0.22%)
Close on Nov 18, 2026Market cap $180.79BP/E 33.6Yield 2.30%
Abbott Laboratories income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 56.6%
- Operating margin
- 15.8%
- Net margin
- 11.6%
- Return on equity, FY2025
- 13.1%
Financial strength
- Current ratio
- 1.38
- Debt to equity
- 0.64
- Debt to assets
- 29.9%
- Cash to current liabilities
- 28.7%
Valuation
- P/E ratio
- 33.6
- Price to sales
- 3.88
- Price to book
- 3.54
- Dividend yield
- 2.30%
See a number that looks wrong?